Condition: Solid Tumor · Melanoma · Sponsor: Toray Industries, Inc
Part 1 • To determine the safety and tolerability of TRK-950 in patients with advanced solid tumors Part 2 • To determine the safety and tolerability of TRK-950 in combination with nivolumab(NIVO) in patients with advanced solid tumors eligible for NIVO therapy Part 3 • To determine the efficacy of TRK-950 in patients with advanced/recurrent unresectable melanoma, who received prior chemotherapy with dacarbazine(DTIC) and for whom no standard therapy exists
This description comes directly from the study's public registry record.
Toray Contact for Clinical Trial Information · +81467-32-9948 · npdd-clinical.toray.mb@mail.toray
Always discuss trial participation with your own doctor first.
| Nagoya City University Hospital | Nagoya, Aichi-ken, Japan | Recruiting |
| National Hospital Organization Kyushu Cancer Center | Fukuoka, Fukuoka, Japan | Recruiting |
| Sapporo Medical University Hospital | Sapporo, Hokkaido, Japan | Recruiting |
| Kumamoto University Hospital | Kumamoto, Kumamoto, Japan | Recruiting |
| Shinshu University Hospital | Matsumoto, Nagano, Japan | Recruiting |
| Niigata Cancer Center Hospital | Niigata, Niigata, Japan | Recruiting |
| Saitama Medical University International Medical Center | Hidaka, Saitama, Japan | Recruiting |
| Shizuoka Cancer Center | Nagaizumi-chō, Shizuoka, Japan | Recruiting |
| National Cancer Center Hospital | Chuo Ku, Tokyo, Japan | Recruiting |
| Keio University Hospital | Shinjuku-Ku, Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05423262